Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2019.105863
Abstract: Cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer antibiotic under development, was designed to retain in vitro activity against Enterobacteriaceae that simultaneously produce metallo-β-lactamase (MBL) and serine-β-lactamase (SBL). Currently, aztreonam (ATM) plus ceftazidime/avibactam (CZA) or meropenem/vaborbactam (M/V)… read more here.
Keywords: cefepime; vitro activity; cza atm; wck 5222 ... See more keywords
725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa
Sign Up to like & getrecommendations! Published in 2019 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofz360.793
Abstract: Abstract Background Pseudomonas aeruginosa (PSA) is an opportunistic pathogen known to cause complications in critically ill patients worldwide. In those at risk of infection with multidrug-resistant strains (MDR-PSA), dual antibiotic therapy is often considered. However,… read more here.
Keywords: cefepime; susceptibility; wck 5222; wck ... See more keywords
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00233-19
Abstract: We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to >256 μg/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to… read more here.
Keywords: wck; cefepime zidebactam; vivo efficacy; 5222 cefepime ... See more keywords
Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01669-19
Abstract: The in vitro activity of WCK 5222 (cefepime-zidebactam) was compared to that of several available combination therapies among 30 clinical carbapenem-resistant Pseudomonas aeruginosa (CRP) strains using gradient diffusion strips. The combinations included nonsusceptible β-lactams (cefepime,… read more here.
Keywords: resistant pseudomonas; cefepime zidebactam; 5222 cefepime; carbapenem resistant ... See more keywords
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
Sign Up to like & getrecommendations! Published in 2022 at "Microbiology Spectrum"
DOI: 10.1128/spectrum.02678-21
Abstract: Antibiotic resistance imposes a severe threat on human health. WCK 5222 is a β-lactam/β-lactamase inhibitor combination that is composed of cefepime and zidebactam. ABSTRACT WCK 5222 (cefepime/zidebactam) is a β-lactam/β-lactamase inhibitor combination that is effective… read more here.
Keywords: wck 5222; wck; resistant pseudomonas; resistance ... See more keywords